No active CDC Level 4 Travel Health Notices exist as of early June 2026, with official listings confirming zero destinations at the “Avoid All Travel” threshold that requires extreme risk and no effective precautions. Recent notices remain at Level 1 or 2 for issues such as hepatitis A in Canada, diphtheria in sub-Saharan Africa, and chikungunya in French Guiana, reflecting contained transmission without escalation to pandemic-scale threats. Historical precedent shows Level 4 issuance only during unprecedented crises like early COVID-19 waves, absent in current surveillance data from the CDC. Trader consensus at 76.5% for “No” by year-end aligns with this stable baseline and lack of novel pathogen emergence or rapid case surges that could alter resolution criteria.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoIl CDC emette un avviso di livello 4 entro il 31 dicembre?
Il CDC emette un avviso di livello 4 entro il 31 dicembre?
Sì
$71,851 Vol.
$71,851 Vol.
31 dic 2026
Sì
$71,851 Vol.
$71,851 Vol.
31 dic 2026
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.No active CDC Level 4 Travel Health Notices exist as of early June 2026, with official listings confirming zero destinations at the “Avoid All Travel” threshold that requires extreme risk and no effective precautions. Recent notices remain at Level 1 or 2 for issues such as hepatitis A in Canada, diphtheria in sub-Saharan Africa, and chikungunya in French Guiana, reflecting contained transmission without escalation to pandemic-scale threats. Historical precedent shows Level 4 issuance only during unprecedented crises like early COVID-19 waves, absent in current surveillance data from the CDC. Trader consensus at 76.5% for “No” by year-end aligns with this stable baseline and lack of novel pathogen emergence or rapid case surges that could alter resolution criteria.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Mercato aperto: Jan 19, 2026, 3:15 PM ET
Volume
$71,851Data di fine
31 dic 2026Mercato aperto
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.No active CDC Level 4 Travel Health Notices exist as of early June 2026, with official listings confirming zero destinations at the “Avoid All Travel” threshold that requires extreme risk and no effective precautions. Recent notices remain at Level 1 or 2 for issues such as hepatitis A in Canada, diphtheria in sub-Saharan Africa, and chikungunya in French Guiana, reflecting contained transmission without escalation to pandemic-scale threats. Historical precedent shows Level 4 issuance only during unprecedented crises like early COVID-19 waves, absent in current surveillance data from the CDC. Trader consensus at 76.5% for “No” by year-end aligns with this stable baseline and lack of novel pathogen emergence or rapid case surges that could alter resolution criteria.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Volume
$71,851Data di fine
31 dic 2026Mercato aperto
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...No active CDC Level 4 Travel Health Notices exist as of early June 2026, with official listings confirming zero destinations at the “Avoid All Travel” threshold that requires extreme risk and no effective precautions. Recent notices remain at Level 1 or 2 for issues such as hepatitis A in Canada, diphtheria in sub-Saharan Africa, and chikungunya in French Guiana, reflecting contained transmission without escalation to pandemic-scale threats. Historical precedent shows Level 4 issuance only during unprecedented crises like early COVID-19 waves, absent in current surveillance data from the CDC. Trader consensus at 76.5% for “No” by year-end aligns with this stable baseline and lack of novel pathogen emergence or rapid case surges that could alter resolution criteria.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti